Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug ...

GSK ( GSK) is preparing a high-stakes push into oncology, lining up five late-stage trials at once for a promising cancer ...

GSK (NYSE:GSK) is beginning to show a more assertive shift in strategy as CEO Luke Miels pushes the company toward higher-risk oncology development, with plans to launch five simultaneous late-stage ...

Overall, TherVacB was found to be safe, well-tolerated, and highly immunogenic among the healthy study participants.

The Montgomery County Economic Development Corp. has hired a new vice president of business development, the second key ...

GSK completes acquisition of Canada-based, clinical-stage biopharma company, 35Pharma Inc: London, UK Thursday, April 16, 2026, 09:00 Hrs [IST] GSK plc announced the completion of ...

Speaking to Fierce at the European Society for Medical Oncology (ESMO) Congress in Berlin at the time, GSK’s Hesham Abdullah, ...

GSK shares have been outperforming the FTSE 100 in 2026. Paul Summers takes a closer look and asks whether this might continue. The post Why is everyone buying GSK shares? appeared first on The Motley ...

(Alliance News) - GSK PLC on Wednesday said it has completed the acquisition of Canada-based clinical stage biopharmaceutical ...

By Bhanvi Satija LONDON, April 12 (Reuters) - British drugmaker GSK's experimental targeted cancer drug Mo-rez has ...

The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million1) in five R&D ...

GSK (GSK.L) received approval from China's National Medical Products Administration for Blenrep, providing a new treatment ...